AN2 Therapeutics (NASDAQ: ANTX) net income
AN2 Therapeutics reported a net loss of $35.2m for fiscal 2025; in fiscal 2024 it reported a net loss of $51.3m. Earnings per share were −$1.16.
AN2 Therapeutics's best year of the last 5 was fiscal 2021. It reported a loss in 5 of those 5 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$35.2m | — | — | −$1.16 |
| 2024 | −$51.3m | — | — | −$1.72 |
| 2023 | −$64.7m | — | — | −$2.74 |
| 2022 | −$41.0m | — | — | −$2.79 |
| 2021 | −$21.5m | — | — | −$10.64 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
AN2 Therapeutics net income compared with its sector
By net income for its latest fiscal year, AN2 Therapeutics ranks 227th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 225th | DiaMedica Therapeutics | −$32.8m | — |
| 226th | Arbutus Biopharma | −$33.5m | −237.9% |
| 227th | AN2 Therapeutics | −$35.2m | — |
| 228th | Immunocore | −$35.5m | −8.9% |
| 229th | Hyperfine | −$35.6m | −262.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of AN2 Therapeutics
- How much did AN2 Therapeutics earn in fiscal 2025?
- AN2 Therapeutics reported a net loss of $35.2m for fiscal 2025. In fiscal 2024 it reported a net loss of $51.3m.
- What are the earnings per share of AN2 Therapeutics?
- They were −$1.16 in fiscal 2025, compared with −$1.72 in fiscal 2024.
- Where does AN2 Therapeutics rank in its sector by net income?
- It ranks 227th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for AN2 Therapeutics come from?
- From the annual report (Form 10-K) that AN2 Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that AN2 Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on AN2 Therapeutics: the AN2 Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.